KDUS

 
Common Stock SEC Reporting - Current
OTCQB
Verified Company Profile 5/10/2017
Contact Info
  • 767 Fifth Avenue
  • New York, NY 10153

Business Description


 
Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Mar 31, 2017 10-Q
CIK 0000911148
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 6500 - Real Estate
Incorporated In: DE, USA
Year of Inc. Not Available
Employees Not Available
Company Officers/Contacts
Hunter C. Gary President, CEO
David Blitz Treasurer, Secretary
Company Directors
Jack Wasserman Chairman
Hunter C. Gary
Peter Liebert
Tara Shuchts
Service Providers
Accounting/Auditing Firm Securities Counsel
Morrison Cohen LLP
909 Third Avenue
New York, NY, 10022-4784
United States
 
Investor Relations Firm

Not Available
Company History
  • Formerly=Cadus Pharmaceutical Corp. until 7-03
KDUS Security Details
Share Structure
Market Value1 $26,550,961 a/o Jul 25, 2017
Authorized Shares 35,000,000 a/o May 09, 2017
Outstanding Shares 26,288,080 a/o May 09, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Par Value 0.01
Shareholders
Shareholders of Record 46 a/o Mar 30, 2016
Short Selling Data
Short Interest 12,444 (8.68%)
Jun 30, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security